Navigation Links
Pharsight Invited to Present on Modeling and Simulation at ARCS Australia Scientific Congress
Date:5/27/2008

Dr. Helen Kastrissios Will Present on Communicating the Value of

Pharmacodynamic Modeling in Clinical Drug Development

MOUNTAIN VIEW, Calif., May 27 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Helen Kastrissios, Ph.D., senior scientist, Pharsight Strategic Consulting Services, has been invited to present to clinical and regulatory professionals attending the Association of Regulatory and Clinical Scientists (ARCS) 17th Annual Congress. The Congress will be held at the Sydney Convention and Exhibition Centre in Sydney, Australia from May 28-30, 2008. Dr. Kastrissios will present on May 30, joining other leading experts from the pharmaceutical industry and academia in a session on clinical applications of pharmacodynamic modeling in drug development.

Dr. Kastrissios' presentation, entitled "Communicating the Value of Pharmacodynamic Modeling in Drug Development," will include several case studies describing how predictive drug-disease models have been used to support dose selection, compare the product profile of a new drug versus marketed competitors utilizing public-source literature data, and communicate model-based results to clinical project teams to support program decision- making. Presentation slides from Dr. Kastrissios' talk will be available at http://www.pharsight.com following the ARCS Congress.

"Model-based drug development has significant value for optimizing drug therapy and for improving the confidence of drug development decisions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Drug development teams can benefit from the quantitative application of drug-disease models to simulate expected clinical responses of new compounds, to support critical program strategies and enhance study design decisions. Pharsight is pleased to participate at the ARCS Congress, where we look forward to sharing our perspective with industry colleagues on the strategic use of modeling and simulation to improve drug development knowledge, productivity and decision- making."

Further information on the ARCS Congress can be found at http://www.arcs.com.au.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharsight Invited to Present on Antiviral Modeling and Simulation at DIA Adherence Workshop
2. Pharsight Strengthens Senior Management Team
3. Pharsight Announces Fiscal Fourth Quarter 2008 and Year End Earnings Release Date and Conference Call
4. Pharsight Signs New Diabetes Meta-Database Customer
5. Pharsight to Present at eClinical Forum
6. Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
7. FDA and Pharsight Continue to Collaborate Under CRADA
8. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
9. Pharsight Achieves $7.3 Million in Quarterly Revenue
10. Pharsight Expands Global Consulting Services Teams
11. Pharsight to Host European Software Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: